Table of Contents
Volume 4 | Issue 4
Publication Date: March 2006- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
238-239 |
The Continuing Challenge of Hormone-Refractory Prostate Cancer Oliver Sartor |
|
Meeting Highlights | ||
240-245 |
Highlights from: the 2006 American Society of Clinical Oncology Prostate Cancer Symposium; San Francisco, CA; February 24-26, 2006 Sabeeha Muneer, G. Kesava Reddy, Aarati Ranganathan, Latha Shivakumar, Oliver Sartor, Vinay K. Jain |
|
Mini-Review | ||
246-248 |
Sorafenib: Recent Update on Activity as a Single Agent and in Combination with Interferon-α2 in Patients with Advanced-Stage Renal Cell Carcinoma G. Kesava Reddy, Ronald M. Bukowski |
|
Comprehensive Reviews | ||
249-256 |
Clinical Utility of Radiolabeled Monoclonal Antibodies in Prostate Cancer Kevin A. David, Matthew I. Milowsky, Lale Kostakoglu, Shankar Vallabhajosula, Stanley J. Goldsmith, David M. Nanus, Neil H. Bander |
|
257-262 |
The Role of Bisphosphonates in the Treatment of Prostate Cancer: Recommendations from an Expert Panel Fred Saad, Celestia S. Higano, Oliver Sartor, Marc Colombel, Robin Murray, Malcolm D. Mason, Andrea Tubaro, Claude Schulman |
|
263-268 |
Chemotherapy for Non–Clear-Cell Renal Cell Carcinoma Kevin A. David, Matthew I. Milowsky, David M. Nanus |
|
Original Contributions | ||
269-274 |
Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480 Peter A. Humphrey, Susan Halabi, Joel Picus, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff, for the Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, and Southwestern Oncology Group |
|
275-280 |
Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial Blase N. Polite, Apurva A. Desai, Beth Manchen, Walter M. Stadler |
|
281-286 |
A Phase I Study of Paclitaxel/Doxorubicin/Thalidomide in Patients with Androgen-Independent Prostate Cancer Robert J. Amato, Harmeet Sarao |
|
287-292 |
Weekly Docetaxel/Estramustine Phosphate in Patients with Increasing Serum Prostate- Specific Antigen Levels After Primary Treatment for Prostate Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network John D. Hainsworth, Anthony A. Meluch, David R. Spigel, Kathleen Yost, Christina Meng, F. Anthony Greco |
|
Case Report | ||
293-295 |
Alkaline Phosphatase Level Increase with Initiation of Hormone Therapy for Prostate Cancer Portends Poor Prognosis with Rapid Progression to Bone Metastases: A Case Report and Review of the Literature Michael W. Brown, Anurag K. Singh |
|
Current Trials | ||
296-298 |
A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Patients with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma Thomas E. Hutson, Ronald M. Bukowski |
|
299-302 |
Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design Kathleen W. Beekman, A. Dimitrios Colevas, Kathleen Cooney, Robert DiPaola, Rodney L. Dunn, Mitchell Gross, Evan T. Keller, Kenneth J. Pienta, Charles J. Ryan, David Smith, Maha Hussain |
|
Clinical Trials | ||
303 |
Selected Clinical Trials in Prostate and Bladder Cancer |
|